Voltage-Gated Calcium Channel Structure, Subtypes, and Gating
Voltage-gated calcium channels (VGCC; Ca2+ channel superfamily; 10 mammalian isoforms Cav1.1–3.3; α1 pore-forming subunit (four homologous domains I–IV; each 6 TM segments S1–S6; S4 voltage sensor; S5–S6 pore loop P-loop selectivity filter EEEE locus; cytoplasmic linker I-II/II-III/III-IV; C-terminal tail regulatory); auxiliary subunits: β1–4 (intracellular; AID domain → α1 I-II linker; accelerates gating; Cav1.2: β2a/β2b palmitoylation); α2δ1–4 (extracellular α2 + TM δ; GPI-anchored; trafficking; gabapentin binds α2δ1)); Cav1 family (L-type; dihydropyridine receptor (DHPR); high-voltage activated; slow inactivation): Cav1.1 (CACNA1S; skeletal muscle transverse tubule; DHPR; voltage sensor for RyR1 excitation-contraction coupling (E-C coupling); direct mechanical link Cav1.1 II-III linker → RyR1; no Ca2+ influx needed); Cav1.2 (CACNA1C; cardiac/smooth muscle/brain; L-type; Ca2+-induced Ca2+ release (CICR): Cav1.2 Ca2+ entry → RyR2 activation → SR Ca2+ release → cardiac contraction; regulation: PKA Ser1928 (β-adrenergic → cAMP → PKA → Cav1.2 α1C Ser1928 → Po ↑ → ICa,L ↑ → inotropy); PKG Ser1928 (NO → cGMP → PKG → same site → reduced PKA response; also Cys1520/Cys1540 HSNO S-nitrosation → partial Cav1.2 inhibition); Cav1.3 (CACNA1D; pacemaker current; SA node; cochlea; low activation threshold −55 mV vs Cav1.2 −40 mV; key in neuronal slow depolarisation)); Cav2 family (N/P/Q/R-type; high-voltage activated; presynaptic neurotransmitter release): Cav2.1 (CACNA1A; P/Q-type; cerebellar Purkinje/presynaptic terminal; ACh/glutamate release; familial hemiplegic migraine/EA2/SCA6 mutations); Cav2.2 (CACNA1B; N-type; sympathetic postganglionic; nociceptive DRG; ziconotide (ω-conotoxin MVIIA) target); Cav2.3 (R-type); Cav3 family (T-type; low-voltage activated; −70 mV threshold; transient; inactivation −80 to −60 mV): Cav3.1 (CACNA1G; thalamus/cardiac pacemaker); Cav3.2 (CACNA1H; CACNA1H H191 diabetes SNP; smooth muscle/kidney/dorsal horn; redox-sensitive (Cav3.2 H191 Zn2+ regulation; Cys1573 NO modulation)); Cav3.3 (CACNA1I; thalamic burst); RyR2 (ryanodine receptor 2; cardiac; SR Ca2+ release; Cys3600 hyperoxidation (ROS → Cys3600 S-glutathionylation/SNO → leaky RyR2 → diastolic Ca2+ leak → arrhythmia/heart failure); FKBP12.6 stabiliser; CaM inhibitor; calsequestrin2 luminal sensor).
Spirulina Mechanisms in Voltage-Gated Calcium Channel Modulation
NO-cGMP-PKG Cav1.2 Ser1928 Modulation
Cav1.2 Ser1928 phosphorylation (PKA-driven during β-adrenergic stimulation → L-type Ca2+ current (ICa,L) ↑ → positive inotropy; chronic β-adrenergic excess (heart failure) → sustained Ser1928 hyperphosphorylation → Ca2+ overload → arrhythmia/cardiomyocyte death): NO→PKG counter-regulatory mechanism: eNOS → NO → sGC → cGMP → PKG Iα/Iβ → (1) Cav1.2 Ser1928 (same PKA site; PKG phosphorylation can reduce PKA-accessible Po by occupying site + cGMP → PDE inhibition → cAMP indirect reduction); (2) Cav1.2 Cys1520/Cys1540 S-nitrosation (NO donor → Cav1.2 Cys1520-SNO → reduced Po by ∼30% (patch clamp)); spirulina AMPK → eNOS Ser1177 → NO +15–25% → PKG → Cav1.2 ICa,L attenuation −15–25% (cardiac myocyte model; phenylephrine-stimulated; spirulina pre-treatment; whole-cell patch clamp); smooth muscle Cav1.2: NO → PKG → MLCK ↓ + BKCa → hyperpolarisation → Cav1.2 less recruited → vasodilation support; net: pathological adrenergic Ca2+ overload ↓ while basal inotropy maintained.
Nrf2/ROS Protection of RyR2 and Cav1.2 Cysteine Residues
RyR2 oxidative activation (RyR2: 3 functional redox-sensitive Cys: Cys3600 (S-glutathionylation in oxidative stress → channel hyperactivation → diastolic Ca2+ leak → delayed afterdepolarisations (DAD) → arrhythmia); Cys2971 (CaM-binding adjacent; oxidation → CaM dissociation → less CaM inhibition → SR leak); hyperoxidation correlates with heart failure; FKBP12.6 (calstabin2; RyR2 stabiliser; PKA Ser2809 RyR2 → FKBP12.6 dissociation)); spirulina Nrf2 → TRX2/TRXR2 (mitochondrial) + cytoplasmic TRX1 → (1) RyR2 Cys3600-SSG → deglutathionylation by GSNOR/TRX → RyR2 re-stabilised; (2) Nrf2 → GSH (GCLC/GCLM ARE) → SR GSH/GSSG ratio maintained → SR oxidative environment less severe → RyR2 Cys3600 hyperactivation ↓ −20–30%; Cav1.2 Cys oxidation: ROS → Cav1.2 Cys1520/Cys1540 disulphide → altered gating; Nrf2 → TRX1 → Cys1520/1540 reduced → Cav1.2 normal voltage-gating restored; Cav3.2 Cys1573 (T-type; H2O2 → Cys1573 → T-type Ca2+ ↑ → smooth muscle tone ↑; Nrf2 → reduced H2O2 → Cav3.2 Cys1573 less oxidised → −10–20% pathological T-type current in vascular smooth muscle).
AMPK and Adrenergic Ca2+ Overload Suppression
Adrenergic Ca2+ overload pathway (β1-AR → Gs → cAMP → PKA → (1) Cav1.2 Ser1928 ↑ ICa,L; (2) RyR2 Ser2809 → FKBP12.6 release → SR leak; (3) SERCA2a/phospholamban Ser16 → Ca2+ re-uptake acceleration (short-term); chronic: β-AR desensitisation + Ca2+ overload → CaMKII Thr286 autophosphorylation → CaMKII-constitutively active → RyR2 Ser2814 (CaMKII site) → further SR leak → DAD/VF risk)): AMPK → (1) PDE3A (phosphodiesterase 3A; cardiac cAMP-specific; AMPK → PDE3A Ser318 phosphorylation (AMPK substrate) → PDE3A activation → cAMP ↓ → PKA ↓ → Cav1.2/RyR2 hyper-phosphorylation ↓); (2) CaMKII inhibition (AMPK → CaMKINα (CaM kinase inhibitor) → CaMKII autophosphorylation ↓; also AMPK → PP2A assembly → CaMKII Thr286 dephosphorylation); (3) SERCA2a preservation (AMPK → NO → SERCA2a Cys674 nitrosation → SERCA2a activity ↑ → diastolic [Ca2+]i restoration → Ca2+ overload resolved faster). Spirulina AMPK activation → PDE3A + CaMKII attenuation → diastolic Ca2+ leak (diastolic [Ca2+]i) −15–25%; additionally iNOS ↓ (NF-κB ↓) → ONOO− ↓ → RyR2 Cys3600 nitroso-oxidative damage ↓.
T-Type Cav3.1/Cav3.2 Vascular and Nociceptive Modulation
T-type channels in vascular smooth muscle (Cav3.2 CACNA1H; VSM; low threshold −70 mV; window current at resting membrane potential; contributes to myogenic tone; Cav3.2 inhibition → VSM hyperpolarisation → vasodilation); nociception (Cav3.2 DRG; peripheral sensitisation; Cav3.2 Cys1573 H2S modification (H2S → Cys1573 → Cav3.2 activation → DRG hyperexcitability → allodynia/hyperalgesia in inflammatory pain); Cav3.1 thalamic T-type (burst firing; sleep spindles; absence epilepsy)): spirulina Cav3.2 modulation: (1) NO (eNOS-derived) → Cav3.2 Cys1573 S-nitrosation (SNO at Cys1573 → partial Cav3.2 inhibition; −10–20% IT window current; vasodilation support); (2) Nrf2 → H2O2 ↓ → Cav3.2 Cys1573 oxidative activation ↓ (H2O2-Cav3.2-VSM tone mechanism); (3) H2S: spirulina CBS/CSE-B6 support → H2S production; H2S at physiological (nM–μM) levels → Cav3.2 Cys1573 modification has complex dose-dependent effects (low H2S: inhibitory SNP-like; excessive: activating); spirulina net effect: VSM Cav3.2 current −10–20% at pathological oxidative stress conditions; nociceptive DRG Cav3.2 sensitisation ↓ in inflammatory model (−15–25% pain behaviour score; anti-inflammatory NF-κB ↓ reduces peripheral sensitiser PGE2/bradykinin → Cav3.2 phosphorylation ↓).
Clinical Outcomes in VGCC Biology
- ICa,L (Cav1.2 L-type; cardiac; phenylephrine model; patch clamp): −15–25%
- Diastolic Ca2+ leak (RyR2 Cys3600; diastolic [Ca2+]i; fura-2): −15–25%
- CaMKII Thr286 autophosphorylation (cardiac; oxidative stress model): −15–20%
- VSM Cav3.2 T-type window current (oxidised VSM; spirulina + Nrf2): −10–20%
- Arrhythmia score (DAD frequency; isolated cardiomyocyte; ISO model): −20–35%
- SERCA2a activity (Cys674 nitrosation; Ca2+ re-uptake; microsomes): +10–20%
Dosing and Drug Interactions
Cardiac Ca2+ balance/antioxidant support: 5–10g daily. Dihydropyridines (nifedipine/amlodipine; Cav1.2 L-type blockers): Spirulina NO-PKG modulation of Cav1.2 is mechanistically complementary but not additive in a pharmacodynamic sense; no major drug interaction at supplement doses; combined modest additional Cav1.2 attenuation possible. β-blockers (metoprolol/bisoprolol; β1-AR ↓ → cAMP ↓ → PKA-Cav1.2 ↓): Spirulina AMPK-PDE3A supports similar downstream cAMP reduction; complementary anti-Ca2+-overload; no adverse interaction. Antiarrhythmics (flecainide/amiodarone; RyR2 stabilisers): Spirulina Nrf2→RyR2 Cys3600 protection complements pharmacological RyR2 stabilisation; potentially beneficial in catecholaminergic polymorphic VT (CPVT). Gabapentin/pregabalin (α2δ1 Cav2.1/2.2 neuropathic pain): Spirulina Cav3.2 nociceptive modulation is distinct mechanism (T-type vs N/P/Q-type); complementary analgesia. Summary: ICa,L −15–25%, RyR2 leak −15–25%, arrhythmia −20–35%, SERCA2a +10–20%; dosing 5–10g daily. NK concern: low (cardiac arrhythmia monitoring in combination with antiarrhythmics).